Ionis

News

EU approves Otsuka's long-acting HAE drug Dawnzera

An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

News

Ionis brings long-acting treatment option to HAE patients

Ionis gets FDA nod for its HAE attack prophylactic treatment Dawnzera, offering less frequent dosing than its rivals.

News

Biogen races into phase 3 with Spinraza follow-up

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

Ionis plans phase 3 for Biogen-rejected Angelman drug

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the

News

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (AT

News

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in

EU approves Otsuka's long-acting HAE drug Dawnzera

Ionis brings long-acting treatment option to HAE patients

Biogen races into phase 3 with Spinraza follow-up

Ionis plans phase 3 for Biogen-rejected Angelman drug

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Ionis

Editor's Picks